Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases... Show more
a producer of pharmaceutical products
Industry PharmaceuticalsMajor
A.I.dvisor indicates that over the last year, SNY has been loosely correlated with PFE. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To SNY | 1D Price Change % | ||
|---|---|---|---|---|
| SNY | 100% | +1.50% | ||
| PFE - SNY | 46% Loosely correlated | +0.53% | ||
| MRK - SNY | 44% Loosely correlated | -0.24% | ||
| BIIB - SNY | 41% Loosely correlated | -1.01% | ||
| GILD - SNY | 38% Loosely correlated | +0.94% | ||
| AMGN - SNY | 37% Loosely correlated | +0.06% | ||
More | ||||
SNY's Aroon Indicator triggered a bullish signal on July 24, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 267 similar instances where the Aroon Indicator showed a similar pattern. In of the 267 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for SNY just turned positive on July 02, 2026. Looking at past instances where SNY's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for SNY crossed bullishly above the 50-day moving average on July 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SNY advanced for three days, in of 307 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved below the 0 level on July 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNY as a result. In of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
SNY moved below its 50-day moving average on July 23, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.272) is normal, around the industry mean (19.722). P/E Ratio (19.538) is within average values for comparable stocks, (28.595). Projected Growth (PEG Ratio) (3.889) is also within normal values, averaging (4.232). SNY has a moderately high Dividend Yield (0.055) as compared to the industry average of (0.031). P/S Ratio (1.982) is also within normal values, averaging (4.183).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock worse than average.